NCT02418559View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Healthy
Interventions
DRUG

JNJ-63623872 (300 mg)

Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.

DRUG

JNJ-63623872 (600 mg)

Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.

DRUG

JNJ-63623872 (1200 mg)

Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.

DRUG

Placebo

Participants will receive placebo tablet orally once on Day 1 under fasted conditions.

Trial Locations (1)

Unknown

Harrow

All Listed Sponsors
lead

Janssen Infectious Diseases BVBA

INDUSTRY

NCT02418559 - A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants | Biotech Hunter | Biotech Hunter